LINX^? reflux management system to bridge the “treatment gap” in gastroesophageal reflux disease: A systematic review of 35 studies

• 作者: Aikaterini Mastoraki Diamantis Tsilimigras Dimitrios Moris Dimitrios Ntourakis Dimitrios Schizas Eleni Papoutsi Orestis Lyros Prodromos Kanavidis Theodore Liakakos Vassilis G Giannakoulis
• 来源期刊: 世界临床病例杂志
• 学科: 医学
• 关键词: LINX^?reflux management system Magnetic SPHINCTER augmentation GASTROESOPHAGEAL REFLUX DISEASE GASTROESOPHAGEAL REFLUX disease-health-related quality of life
• 年，卷（期）: 2020,（2）
• 页码范围: 294-305
• 页数: 12页
• 分类号: R57

摘要

BACKGROUND Gastroesophageal reflux disease(GERD) occurs when the reflux of stomach contents causes troublesome symptoms and/or complications. When medical therapy is insufficient, surgical therapy is indicated and, until now, Laparoscopic fundoplication(LF) constitutes the gold-standard method. However, magnetic sphincter augmentation(MSA) using the LINX^? Reflux Management System has recently emerged and disputes the standard therapeutic approach.AIM To investigate the device’s safety and efficacy in resolving GERD symptoms.METHODS This is a systematic review conducted in accordance to the PRISMA guidelines.We searched MEDLINE, Clinicaltrials.gov, EMBASE, Cochrane Central Register of Controlled Trials CENTRAL databases from inception until September 2019.RESULTS Overall, 35 studies with a total number of 2511 MSA patients were included and analyzed. Post-operative proton-pump inhibitor(PPI) cessation rates reached 100%, with less bloating symptoms and a better ability to belch or vomit in comparison to LF. Special patient groups(e.g., bariatric or large hiatal-hernias)had promising results too. The most common postoperative complication was dysphagia ranging between 6% and 83%. Dilation due to dysphagia occurred in 8% of patients with typical inclusion criteria. Esophageal erosion may occur in up to 0.03% of patients. Furthermore, a recent trial indicated MSA as an efficient alternative to double-dose PPIs in moderate-to-severe GERD.CONCLUSION The findings of our review suggest that MSA has the potential to bridge the treatment gap between maxed-out medical treatment and LF. However, further studies with longer follow-up are needed for a better elucidation of these results.